Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration

Figures & data

Table 1 Individual Values for Vision Recovery Velocity (VRV), Injection Momentum (InjMom), and Vision Recovery Acceleration (VRA) for Bevacizumab, Ranibizumab, Aflibercept, and Brolucizumab According to Each Clinical Study Included in the Model Analysis

	VRV (Letters/Month)	InjMom (Number of Injections ∙ (Letters/Month))	VRA (Letters/Month^2)
Bevacizumab
CATT Monthly	0.3	7.02	−0.02
CATT PRN	0.19	2.71	−0.02
IVAN Monthly	0.23	5.3	−0.02
IVAN PRN	0.15	1.9	−0.02
LUCAS T&E	0.31	5.61	−0.03
Ranibizumab
ANCHOR Monthly	0.45	9.5	−0.04
CATT Monthly	0.34	7.58	−0.02
CATT PRN	0.26	3.25	−0.02
HARBOR Monthly	0.38	8.11	−0.04
HARBOR PRN	0.33	4.38	−0.03
IVAN Monthly	0.2	3.68	−0.03
IVAN PRN	0.17	3.25	−0.02
MARINA Monthly	0.28	6.6	0.02
LUCAS T&E	0.28	4.4	−0.03
Aflibercept
VIEW Monthly PRN	0.32	5.07	−0.04
VIEW q8 Weeks	0.32	3.55	−0.03
HAWK q8 Weeks	0.57	3.97	−0.01
HARRIER q8 Weeks	0.56	3.91	−0.01
Brolucizumab
HAWK q12 Weeks	0.55	3.58	−0.01
HARRIER q12 Weeks	0.56	3.63	−0.01

Table 2 Summary Values for Vision Recovery Velocity (VRV), Injection Momentum (InjMom), and Vision Recovery Acceleration (VRA) for Bevacizumab, Ranibizumab, Aflibercept, and Brolucizumab

Agent	VRV (Letters/Month)	InjMom (Number of Injections ∙ (Letters/Month))	VRA (Letters/Month^2)
Bevacizumab	0.24	4.51	−0.02
Ranibizumab	0.30	5.64	−0.02
Aflibercept	0.44	4.12	−0.02
Brolucizumab	0.56	3.61	−0.01

Figure 1 Graphical summary of vision recovery velocity (VRV), injection momentum (InjMom), and vision recovery acceleration (VRA) for bevacizumab, ranibizumab, aflibercept, and brolucizumab.